Innovazione & Ricerca

Clinical trials database

Le informazioni riportate in questa pagina riguardano gli studi clinici condotti dal Gruppo Menarini e non hanno finalità promozionali o di marketing, né intendono sostituirsi al parere del medico, al quale è sempre e comunque demandata la scelta della terapia più opportuna per ciascun paziente.

Clinical Trials Results


DATASHARING


LOGIN

Oncology Analgesia Cardiovascular & Metabolic Gastrointestinal disorders Respiratory & Allergology Other
Medical Condition
Compound
Phase
Status
Requirements
 
Acute Myeloid Leukemia
SEL24/MEN1703
I/II
Recruiting
=18 Years
Read More
A Phase I/II Study of SEL24 in Patients with Acute Myeloid Leukemia (DIAMOND-01)
Advanced Solid Tumors
SL-901
I
Recruiting
=18 Years
Read More
A Phase 1, Open-label, Dose-escalation Study of the PI3K Inhibitor SL-901 in Patients
Chronic Myelomonocytic Leukemia or Myelofibrosis
Tagraxofusp / SL-401
II
Recruiting
=18 Years
Read More
Tagraxofusp (SL-401) in Patients with Chronic Myelomonocytic Leukemia (CMML) or Myelofibrosis (MF)
Colorectal Cancer
MEN1611
I/II
Recruiting
=18 Years
Read More
MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)
Breast Cancer
MEN1611
I
Active not recruiting
=18 Years
Read More
MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer (B-PRECISE-01)
Acute Myeloid Leukemia
MEN1112
I
Terminated
=18 Years
Read More
First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia (ARMY-1)
Advanced Solid Tumors
Felezonexor / SL-801
I
Terminated
=18 Years
Read More
A Phase 1 Study of SL-801, a Reversible Inhibitor of Nuclear Export, in Patients with Advanced Solid Tumors
Ovarian cancer
Abagovomab
II/III
Terminated
=18 Years
Read More
Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients (MIMOSA)
Solid Tumors/ Non-Hodgkin Lymphoma
MEN1309
I
Terminated
=18 Years
Read More
MEN1309 Intravenous Infusion in Patients With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory Non-Hodgkin Lymphoma Phase I Study (CD205-SHUTTLE)

Recruitment status:

NOT YET RECRUTING: The study has not started recruiting participants
RECRUITING: The study is currently recruiting participants.
ACTIVE, NOT RECRUITING: The study is ongoing (that is, participants are receiving an intervention or being examined), but potential participants are not currently being recruited or enrolled.
COMPLETED: The study has ended normally, and participants are no longer being examined or treated (that is, the "last subject, last visit" has occurred).
TERMINATED: The study has stopped recruiting or enrolling participants early and will not start again. Participants are no longer being examined or treated.
WITHDRAWN: The study stopped early, before enrolling its first participant.